CURRICULUM VITAE
`S. NARASIMHA MURTHY
`
` OFFICE
`
`
`
`RESIDENCE
` Associate Prof-Pharmaceutics
`
`501 Bowie Drive
` 113 Faser Hall
`Oxford, MS 38655, USA
`
` The University of Mississippi
`Tel : 662-513-0024
`
`
`Cell: 662-202-4929
` University, MS 38677
`
`
`
` Tel : 662-915-5164
`
`
`
`
` Fax:: 662-915-1177
`
` E-mail: murthy@olemiss.edu
`Research Group : http://www.olemiss.edu/~murthy
`
`
`EDUCATION
`Bachelor of Pharmacy (Bangalore University, India)
`1988-1992
`1992-1994 Master of Pharmacy- Pharmaceutics (Bangalore University, India)
`1996-2002
`PhD-Pharmaceutics (Bangalore University, India)
`2002-2005
`Postdoctoral Research Associate- Molecular and Cellular Biophysics at
`Roswell Park Cancer Institute, Buffalo, NY, USA.
`
`
`
`
`
`POSITIONS AND INSTITUTES
`1994-2002 Assistant Professor (Pharmaceutics)- M.S.R College of Pharmacy, India
`2005-2006 Assistant Professor (Pharmaceutics)-Ohio Northern University, OH
`2006-2011 Assistant Professor (Pharmaceutics) – The University of Mississippi, MS
`2011- Associate Professor (Pharmaceutics)-The University of Mississippi, MS
`2013- Founder-Director, Institute for Drug Delivery and Biomedical Research,
` Bangalore India (www.IDBResearch.Org)
`
`
`OTHER AFFILIATIONS
` Research Associate Professor- Research Institute of Pharmaceutical Sciences
`Chair-Dermatopharmaceutics Focus Group-AAPS
`Member- AAPS Member groups Co-ordination Committee
`Manager-Phoretek Pharma LLC, Oxford, MS.
`Chief Scientific Advisor-Dermaperm Research Inc, Bangalore, India.
`Editor in Chief-Research and Reports in Transdermal Drug Delivery
`Member of the Roaster of Central Scientific Review, Dermatology, Rheumatology and
` Inflammation Committee, CRS, National Institutes of Health.
`
`Editorial Advisory Board Member
`Journal of Pharmaceutical Research
`Drug Development and Industrial Pharmacy
`Recent Patents on Drug Delivery & Formulation.
`
`MYLAN - Ex. 1006, p. 1
`
`

`

`Clinical Medicine-Dermatology.
`ScientiaPharmaceutica.
`The Open Dermatology Journal
`Journal of Interactive experiment and protocol
`
`
`Research Grant Reviewer
` National Institutes of Health, USA
` Wellcome Foundation, UK
` British Skin Foundation, UK
` Ohio Northern University, Ada, OH
` Department of Innovation, Government of Italy
` Portuguese Foundation for Science and Technology
`
`
` Ph.D Dissertation Reviewer/Evaluator
` The University of Mississippi, Oxford, MS
` Jadavpur University, Kolkata, India.
` Manipal Academy of Higher Education, Manipal, India.
` Vinayaka Missision University, Coimbatore, India
` Tamilnadu MGR University, Chennai, India
` Berhampur University, Orissa, India.
`
`
`
`
`
`
`
` $1.250.000
`
`
`AWARDS & RECOGNITION
`2013 Top Reviewer by the American Pharmacists Association (APhA)
`2011 Top Reviewer by the American Pharmacists Association (APhA).
`2011 Top Reviewer” by Elsevier Publications Ltd.
`2010 Certification of “Highly cited publication in Journal of Dermatological Sciences”.
`2010 New Investigator Award- The University of Mississippi School of Pharmacy.
`2009 Top Reviewer by the American Pharmacists Association (APhA)
`2008 “Global Indus Technovator’s Award” from MIT, Boston, MA.
`2008 Top Reviewer by the American Pharmacists Association (APhA)
`2007 Faculty Research Fellow. The University of Mississippi.
`2006 Endowed Chair for Research at Ohio Northern University, Ada, OH.
`2006- Biography included in Marquis Who’s Who in the World (23rd Edn)
`2005- Biography included in Marquis Who’s Who in Science and Engineering
`2005- Biography included in Marquis Who’s Who is Health and Healthcare.
`
`RESEARCH GRANTS (PRINCIPAL INVESTIGATOR-MURTHY)
`
`2014-19 TOPICALS PRODUCTS AND CQA
`
`
`
`(1U01FD005233-01) funded by USFDA
`
`2014-15
`
`
`
`
`
`NAIL PENETRATION OF ANTIFUNGAL DRUG
`(ARNO THERAPEUTICS, USA)
`
`
`
` $22,500
`
`MYLAN - Ex. 1006, p. 2
`
`

`

`Dermal Delivery of therapeutics using Cyclodextrins $40,000
`2014-15
` (Ligand Ltd, CA)
`
`2013
`
`
`
`2013-14
`Role: PI
`
`2012-14
`Role-PI
`
` $369,000
`
`
`A Novel method for treating Chronic pain
`2012-14
`Role-PI National Institute of Neurological Disorders and Stroke (NINDS)
`
` $138,000
`
`
`
`Transdermal delivery of iron
`2010-12
`Role-PI National Institute of Neurological Disorders and Stroke (NICHD)
`
`2010
`Role-PI
`
`2009-11
`Role: PI
`
`2008-09
`Role: PI
`
`
`
`
`Travel grant-3rd European Cyclodextrin Conference in Turkey.
`Cydex Pharmaceuticals, La Jolla, CA
`
`
`
`
`
`$4,000
`
`Formulation of Intrathecal Controlled Release Microspheres
`Small grant program (COBRE awarded to Univ. Mississippi) $50,000
`
`Taste Masking of API’s by Hot melt Extrusion
`Roquette Pharma, Chicago, IL $10,000
`
`Bioadhesive properties of Nail lacquers
`Chanelle Group, France
`
`
`
`
`
`
`
`
`
` $5000
`
`Vehicles to enhance nose to brain bioavailability of drugs
`CORE-NPN (NCRR)-Junior Investigator
`
` $264,000
`
` $140,000
`
`Rapid transdermal delivery of drugs.
`Transport Pharmaceuticals Inc.
`
`
`Electropulsation mediated Drug therapy for Onychomycosis $150,000
`National Institute of Biomedical Engineering and Bioimaging (NIBIB)
`
`2008-10
`Role: PI
`
`2007-08
`Role: PI
`
`2007-08
`Role: PI
`
`2007-2009 Enhancement of brain uptake of Neurotrophins
`Role:PI CORE-NPN (NCRR)-Small grants program
`
`
`
`2006-2009
`Role: PI
`
`2005-06
`Electret Effects on the Skin permeability
`Role: PI Rad Elec Inc., MD
`
`
`
`
`Iontophoretic trans-ungual Delivery of Drugs”
`Transport Pharmaceuticals Inc.
`
` $128,000
`
`Noninvasive transcorneal drainage of aqueous humor
`Faculty Research Fellow-2007, Univ. of Mississippi. $ 8,000
`
`Electroporation and transcutaneous extraction of drugs $145,000
`National Institute of Arthritis Musculoskeletal and Skin diseases (NIAMS)
`
`
`
` $20,000
`
`
`
`
`
` $ 10,000
`
`MYLAN - Ex. 1006, p. 3
`
`

`

`
`2005-06 Effect of electroporation on transcorneal water permeation
`Role: PI Endowed Chair Research Grant-Ohio Northern University
` $ 21,000
`
`2005-06
`Role-PI
`
`2001 Travel grant from Karnataka State Pharmacy Council for presentation of
` Research paper at FIP2000, Sydney, Australia. 2001. Rs 15,000
`
`
`
`ONU Teaching with Technology Grant
`Office of Dean-Ohio Northern University $ 5,000
`
`PUBLICATIONS
`
`BOOKS- CHIEF EDITOR
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`BOOK CHAPTERS (Eleven)
`
`Chapters authored in the book “Advances in Pharmaceutical Technology” Edited by
`Shobharani R. Hiremath. (Publisher: Orient Longman).
`1. Transdermal drug delivery
`2. Ocular drug delivery
`3.
`Intranasal drug delivery
`4. Buccal drug delivery
`5.
`Implant Drug delivery systems
`
`Chapter authored in the book “Minimally invasive techniques of drug delivery” edited by
`Dr.Kulkarni, DPT laboratories. (CRC Press)
`6. Dermal and Transdermal drug delivery
`
`Chapter authored in the book “Percutaneous Enhancement Techniques edited by
`Dr.Howard Maibach.
`7. Therapeutic applications of Transdermal Electroporation
`
`MYLAN - Ex. 1006, p. 4
`
`

`

`
`Chapters authored in the book “Dermatokientics of therapeutic agents” edited by
`S.Narasimha Murthy
`8. Formulation approaches to modulate the dermatokinetics of drugs
`
`Chapters authored in the book “Topical Nail Products and Ungual Drug Delivery” edited
`by S.Narasimha Murthy
`9. Topical nail formulations
`10. Approaches to enhance ungual and trans-ungual drug delivery.
`11. In vitro and in vivo models to evaluate topical nail formulations.
`
`PEER REVIEWED PUBLICATONS
`1. Maurya A, Murthy S.N. Pretreatment with Skin Permeability Enhancers: Importance
`of composition and duration of treatment in diclofenac delivery. J.Pharm.Sci. 2014:
`103(4), 1178-83
`2. Juluri, A., Murthy, S. N (2014). Transdermal iontophoretic delivery of a liquid
`lipophilic drug by complexation with an anionic cyclodextrin. Journal of Controlled
`Release, 2014:189, 11-18.
`3. Manda P, Angamuthu M, Hiremath S, Murthy S.N. Iontophoretic drug delivery for
`the treatment of scars” J.Pharm Sci 2014,:03(6), 1638-42
`4. Jo.S, Murthy S.N et al., Quinone Propionic Acid-based Redox-triggered Polymer
`Nanoparticles for Drug Delivery: Computational Analysis and in Vitro Evaluation.
`J.Applied. Polymer.Sci (In Press)
`5. Shivakumar H.N, Repka M.A, Murthy S.N. Delivery of drugs across the nail plate.
`J.Drug.Del.Sci. Tech. 2014.
`6. Abhshek J, Shivakumar H.N, Vanakja K, Murthy S.N. Passive approaches of
`transcutaneous vaccine delivery J.Drug.Del.Sci. Tech. 2014
`7. Modepalli N, Murthy S.N. Irontophoresis for treating Anemia. J.Drug.Del.Sci. Tech.
`2014
`8. Angamuthu M, Murthy S.N. Controlled release Intralesional Injection of Terbinafine
`hydrochloride for treating onychomycosis. J.Pharm.Sci 2014:103(4), 1178-1183.
`9. Perumal. O., Murthy S. N., & Kalia, Y. N. The Development of Modern Transdermal
`Drug Delivery Systems and Future Trends. Skin Pharmacol. Physiol., 2013: 26(4-6),
`331-342.
`10. Murthy, S. N. Iontophoresis for treating nail diseases. Therapeutic delivery, 2013:
`4(6), 647-650.
`11. Loria, M. J., White, S. W., Robbins, S. A., Salmeto, A. L., Hymel, K. A., Murthy, S. N., &
`Sufka, K. J. Brain-derived neurotrophic factor response in vulnerable and resilient
`genetic lines in the chick anxiety-depression model. Behavioral Brain Res.. 2013:
`245, 29-33.
`12. Juluri A, Modepalli N, Shivakumar H.N, Repka M, Jo.S, Murthy S.N., Minimally
`invasive transdermal delivery of iron dextran using microneedles. J.Pharm.Sci.
`2013:102(2), 987-993.
`
`MYLAN - Ex. 1006, p. 5
`
`

`

`13. Juluri A, Reddy P, Murthy S.N.Transdermal Iontophoretic Delivery of Propofol, a
`General Anesthetic in the form of its Phosphate Salt. J.Pharm.Sci. 2013:102(3), 500-
`507.
`14. Modepalli N, Repka, M, Jo.S, Murthy S.N. Microporation and Irontophoresis for
`treating iron deficiency anemia. Pharm Res. 2013: 30(3), 889-98.
`15. Vaka SRK, Shivakumar HN, Repka M.S, Murthy S.N. Formulation and Evaluation of
`carnosic acid nanoparticles for nose to brain delivery. J.Drug.Targ. 2013: 21(1), 44-
`53.
`16. Murthy S. N. Transdermal drug delivery: approaches and significance. Research and
`Reports in Transdermal Drug Delivery, 2012:1, 1-2.
`17. Nair A.B, Vaka Siva Ram K, Murthy S.N. In vitro and In vivo evaluation of a hydrogel
`based prototype transdermal patch system of alfuzosin hydrochloride. Pharm Dev
`Technol. 2012: 17(2),158-63.
`18. Manda P, Sammeta S M, Repka MA, Murthy S.N. Iontophoresis across the proximal
`nail fold to target drugs to the nail matrix. J Pharm Sci. 2012: 101(7), 2392-2397.
`19. Shivakumar, H. N., Juluri, A., Desai, B. G., & Murthy S. N. Ungual and transungual
`drug delivery. Drug Dev & Ind Pharm., 2012: 38(8), 901-911.
`20. Vaka S.R, Murthy S.N. Repka, M.A and Nagy T. Upregulation of edogenous
`neurotrophin lelves in the brain by intrnasal administration of carnosic acid.
`J.Pham.Sci, 2011: 100(8) 3139-45.
`21. Juluri A, Vaka Siva Ram Kiran, Shivakumar HN, Murthy S.N. Early stage technologies
`for dermal and transdermal drug delivery: Magnetophoresis and Electret.
`Transdermal Magazine. 2011: 3(6), 19-21.
`22. Nair A.B, Vaka Siva Ram Kiran, Murthy S.N.Trans-ungual delivery of terbinafine by
`iontophoresis in onychomycotic nails. Drug Dev Ind Pharm. 2011: 37(10), 1253-1258.
`23. Vaka Siva Ram Kiran, Murthy S.N, O'Haver J, Repka M.A.A Platform for Predicting
`and Enhancing Model Drug Delivery across the Human Nail Plate. Drug Dev Ind
`Pharm. 2011: 37(1), 72-79.
`24. Sammeta S.M, Repka M.A, Murthy S.N. Magnetophoresis in combination with
`chemical enhancers for transdermal drug delivery. Drug Dev Ind Pharm. 2011: 37(9),
`1076-1082..
`25. Vaka Siva Ram Kiran, Shivakumar H.N, Murthy S.N.Constant Voltage Iron”tophoresis
`Pharm Dev Technol. 2011: 16(5), 483-488
`26. Vaka SRK, Murthy S.N, Balaji A, Repka M.A. Delivery of brain derived neurotrophic
`factor via nose to brain pathway. Pharm. Res. 2012: 29(2), 441-447.
`27. Manda P, Hargett J.K, Vaka Siva Ram Kiran, Repka M.A, Murthy S.N., Delivery of
`cefotaxime to the brain via intranasal administration. Drug Dev Ind Pharm. 2011:
`37(11), 1306-1310.
`28. Murthy S.N, Sammeta S.M, Bowers C. Magnetophoresis for enhancing transdermal
`drug delivery: mechanistic studies and patch design. J Control Release. 2010: 148(2),
`197-203
`29. Nair A.B, Murthy S.N. Effect of polyethylene glycols on the trans-ungual delivery of
`terbinafine. Curr. Drug. Deliv. 2010: 7(5), 407-14.
`30. Vaka S.R.K, Murthy S.N. Enhancement of nose-brain delivery of therapeutic agents
`
`MYLAN - Ex. 1006, p. 6
`
`

`

`using peppermint oil for treating neurodegenerative diseases. DiePharmazie. 2010:
`65, 690-692
`31. Shivakumar H.N, Vaka S.R.K, Murthy S.N. Bilayered nail lacquer of terbinafine
`hydrochloride for treating onychomycoses. J. Pharm. Sci. 2010: 99(10), 4267-4276.
`32. Murthy S.N, Nair A.B, Hammer N, Vaka S.R.K, Wright A.E. Dermatokinetics of
`nanoparticles (25nm). Int. J. Innovative Pharm. Res. 2010: 1(2), 37-43.
`33. Sammeta S.M, Vaka S.R.K, Murthy S.N. Transcutaneous electroporation mediated
`delivery of doxepin-HPCD complex: a sustained release approach for treatment of
`postherpetic neuralgia. J Control Release. 2010: 142(3), 361-67.
`34. Sammeta S.M, Murthy S.N. ChilDrive-A technique to deliver drugs to the synovial
`cavity via topical administration. Pharm. Res. 2009: 26(11), 2535-40.
`35. Charoo N.A, Rahman Z, Repka M.A, Murthy S.N. Electroporation: An avenue for
`transdermal Delivery. Curr. Drug. Deliv. 2010: 7(2), 125-36.
`36. Shivakumar H.N, Vaka S.R.K, Murthy S.N. Albumin microspheres for oral delivery of
`iron. J. Drug Target. 2010: 18(1), 36-44.
`37. Nair A.B, Kim H.D, Davis S.P, Etheredge R, Barsness M, Friden P.M, Murthy S.N. An ex
`vivo toe model used to assess applicators for iontophoretic ungual delivery of
`terbinafine. Pharm. Res. 2009: 26(9), 2194-2201.
`38. Nair, A.B., Sammeta, S.M., Kim, H.D., Chakraborty, B., Friden, P.M and Murthy, S.N.
`Alteration of the diffusional barrier property of the nail leads to greater terbinafine
`drug loading and permeation. Int. J. Pharm. 2009: 375(1), 22-27.
`39. Murthy S.N, Vaka S.R.K, Sammeta S.M, Nair A.B. TranScreen-N: Method for rapid
`screening of trans-ungual drug delivery enhancers. J. Pharm. Sci. 2009: 98(11), 4264-
`4271.
`40. Nair A.B, Kim H.D, Chakraborty B, Singh J, Zaman M, Gupta A, Friden P.M, Murthy
`S.N. Ungual and Trans-ungual Iontophoretic Delivery of Terbinafine for the Treatment
`of Onychomycosis .J. Pharm. Sci. 2009: 98(11), 4130-40.
`41. Murthy S.N, Vaka S.R.K.
`Irontophoresis-Transdermal delivery of
`iontophoresis. J. Pharm. Sci. 2009: 98 (8), 2670-76.
`42. Vaka S.R.K, Sammeta S.M, Day L.B, Murthy S.N. Delivery of Nerve Growth Factor to
`brain via intranasal administration and enhancement of brain uptake. J. Pharm. Sci.
`2009: 98(10), 3640-46.
`43. Sammeta S.M, Vaka S.R.K, Murthy S.N. Dermal drug levels of antibiotic (cephalexin)
`determined by electroporation and transcutaneous sampling (ETS) technique. J.
`Pharm. Sci. 2009: 98 (8), 2677-85.
`44. Murthy S.N, Sammeta S.M, Vaka S.R.K. OcuDrain-E - A noninvasive technique for
`reduction of intraocular pressure. Int. J. Pharm. 2009: 369 (1): 92-95.
`45. Sammeta S.M, Vaka S.R.K, Murthy S.N. Transcutaneous sampling of ciprofloxacin
`and 8-methoxypsoralin by electroporation (ETS) technique. Int. J. Pharm. 2009:
`369(1-2): 24-29.
`46. Sammeta S.M, Vaka S.R.K, Murthy S.N. Transdermal drug delivery enhanced by low
`voltage electropulsation (LVE). Pharm. Dev. Technol. 2009: 14(2): 159-164.
`47. Nair A.B, Sammeta S.M, Vaka S.R.K, Murthy S.N. A study on the effect of inorganic
`salts in trans-ungual drug delivery of terbinafine. J. Pharm. Pharmacol. 2009: 61(4),
`
`iron by
`
`MYLAN - Ex. 1006, p. 7
`
`

`

`431-37.
`48. Nair A.B, Vaka S.R.K, Sammeta S.M, Kim H.D, Friden P.M, Chakraborty B, Murthy S.N.
`Trans-ungual iontophoretic delivery of terbinafine hydrochloride. J. Pharm.Sci. 2009:
`98(5), 1788-96.
`49. Vaka S.R.K, Sammeta S.M, Day L.B, Murthy S.N. Transcorneal iontophoresis for
`delivery of ciprofloxacin hydrochloride. Curr. Eye. Res. 2008: 33(8), 661-667.
`50. Sammeta S.M, Vaka S.R.K, Mathur S.K, Murthy S.N. Non invasive transcutaneous
`sampling of glucose by electroporation. J Diabetes Sci Technol. 2008: 2(2), 250-254.
`51. Murthy S.N, Zhang S. Electroporation and transcutaneous sampling (ETS) of
`acyclovir. J. Derm. Sci. 2008:.49(3), 249-251.
`52. Murthy S.N, Boguda V.A, Payasada K. Electret enhances Transdermal Drug
`Permeation. Biol. Pharm. Bull. 2008: 31(1),99-102.
`53. Murthy S.N, Waddell D, Bowers C.P. Iontophoretic permselectivity of nail plate. J.
`Derm .Sci. 2007: 46(2), 150-152.
`54. Murthy S.N, Wiskirschen D, Bowers C.P. Iontophoretic drug delivery across human
`nail. J. Pharm. Sci. 2007: 96(2), 305-311.
`55. Murthy S.N, Zhao Y, Marlan K, Kazim L.T, Hui S.W, Sen A. Lipid and electroosmosis
`enhanced transdermal delivery of insulin by electroporation. J. Pharm. Sci, 2006:
`95(9) 2041-2050.
`56. Murthy S.N. Zhao Y, Hui S.W, Sen A. Synergistic effect of anionic lipid enhancer and
`electroosmosis for transcutaneous delivery of insulin. Int. J. Pharm. Sci. 2006: 326
`(1),1-6.
`57. Murthy S.N, Vishwanath. B. N-octyl-beta-thioglucoside enhances the transdermal
`permeation of ketotifen. Pharmazie. 2006: 1, 75-76.
`58. Murthy S.N, Bryant. B, Mehta V. Recent advances in neonatal therapy. Annals of
`Pharmacotherapy. 2006. 40: 710-719.
`59. Murthy S.N, Vishwanath B, Bharath S. Bioadhesive tablets for controlled
`transdermal delivery of drugs. PDA journal of Pharmaceutical Sciences 2005: 59(6),
`355-359.
`60. Murthy S.N, Zhao Y, Hui S.W, Sen A. Electroporation and Transcutaneous extraction
`for Pharmacokinetic studies of Drugs. J. Control. Release. 2005: 105,132-141.
`61. Zhao Y, Murthy S.N, Sen A, Hui S.W. Induction of cytotoxic T lymphocytes by
`electroporation-enhanced needle-free skin immunization vaccine. Vaccine, 2006:
`24(9), 1282-1290.
`62. Murthy S.N, Sen A, Zhao Y, Hui S.W. Cyclodextrin enhanced transdermal delivery of
`piroxicam and Carboxyfluorescein by electroporation. J. Control. Release. 2004:
`99(3), 393-402.
`63. Murthy S.N, Hiremath S.R, Paranjothy K.L.K. Clinical Pharmacokinetic and
`Pharmacodynamic evaluation of transdermal drug delivery systems of salbutamol
`sulfate. Int. J. Pharm. 2004: 287(1), 47-53.
`64. Murthy S.N, Sen. A, Hui S.W. Surfactant enhanced transdermal delivery by
`electroporation. J. Control. Release. 2004: 98 (2), 307-315.
`65. Murthy S.N, Sen. A, Zhao Y, Hui S.W. Temperature
`influences the post-
`electroporation permeability state of skin J. Pharm. Sci, 2004: 93(4), 908-915.
`
`MYLAN - Ex. 1006, p. 8
`
`

`

`66. Murthy S.N, Hiremath S.R, Paranjothy K.L.K. Preparation and Evaluation of
`transdermal drug delivery systems of carboxymethyl guar. Int. J. Pharm. 2004: 272
`(10), 11-18.
`67. Murthy S.N, Sen. A, Zhao Y, Hui S.W. pH influences the post-pulse permeability
`state of the skin after electroporation. J. Control. Release. 2003: 93, 49-57.
`68. Murthy S.N, Hiremath S.R. Preformulation evaluation of transdermal films of
`hydroxypropyl methylcellulose and sodium carboxymethyl cellulose. Int. J. Pharm.
`Excipients, 2002: 12, 34-38.
`69. Murthy S.N, Hiremath S.R, Paranjothy K.L.K . Preformulation evaluation of
`transdermal films of sodium carboxymethyl guar. Int. J. Pharm. Excipients, 2001:
`Jan-Mar, 13-17.
`70. Murthy S.N, Hiremath S.R. Preparation and evaluation of controlled release
`transdermal drug delivery systems of salbutamol sulfate-theophylline. Drug Dev. Ind.
`Pharm, 2001: 27(10), 1057-1062.
`71. Murthy S.N, Hiremath S.R, Physical versus chemical permeation enhancers in
`transdermal drug delivery. AAPS PharmScitech, 2001: 2(1), 1-5.
`72. Murthy S.N, Mahesh S, Sanoferjan, Swamy N. Formulation and Evaluation of beta-
`cyclodextrin complexes of Tenoxicam. Indian. J. Pharm. Sci, 2000: 62(2), 119-123.
`73. Murthy S.N. Magnetophoresis, A novel approach in transdermal delivery of Drugs.
`Die Pharmazie, 1999: 54, 377.
`74. Murthy S.N, Hiremath S.R. Effect of magnetic field on the transdermal permeation
`of Salbutamol sulfate and terbutaline sulfate. Indian drugs: 1999, 36(10), 663-665.
`75. Mahesh S, Murthy S.N, Bharath S, Madhavan V.Modification of physical
`characteristics of DCP by co-drying with beta-cyclodextrin. Indian drugs, 1999: 36(9),
`601-604.
`76. Murthy S.N, Hiremath S.R. A Thermodynamical approach to the diffusion of
`terbutaline sulfate from the transdermal films. Indian J. Pharm. Sci., 1999: 61(3),
`141-143.
`77. Mahesh S, Murthy S.N, Swamy N, Paranjothy K.L.K. Formulation and evaluation of
`Isopropyl antipyrine oral suspensions. Indian. J. Pharm. Sci, 1998: 60(2), 90-95.
`78. Murthy S.N, Hiremath S.R Comparative pharmacokinetic and pharmacodynamic
`evaluation of oral versus transdermal formulations of terbutaline sulfate. Indian
`Drugs, 1998: 35(1), 34-36.
`79. Murthy S.N, Preparation and Evaluation of floating microspheres by core
`solubilization technique. Indian Drugs, 1997: 34(11), 674-675.
`80. Murthy S.N. Biodegradable polymer matrix based ocuserts of diclofenac sodium.
`Indian Drugs, 1997: 34(6), 336-338.
`81. Murthy S.N, Hamsa V. Enhancer synergism of propylene glycol and PEG-400 in
`terbutaline sulfate - Transdermal drug delivery systems. Indian Drugs, 1997: 34(4),
`224-226.
`82. Jacob VC, Murthy S.N. Saravanan J. Spectrophotometric estimation of busipirone
`hydrochloride in pharmaceutical formulation. Indian drugs. 1997: 34(1), 24-25
`83. Murthy S.N, Hamsa V. Drug release studies from terbutaline sulfate films across
`human cadaver skin. Indian. J. Pharm. Sci, 1997: 64(2), 75-78.
`
`MYLAN - Ex. 1006, p. 9
`
`

`

`84. Murthy S.N, Bhaskaran S, Hamsa V. Comparative release studies of transdermal
`films of terbutaline sulfate across various diffusion barriers. Indian. J. Pharm. Sci,
`1996: 58(4), 150-153.
`85. Murthy S.N, Hamsa V, Bhaskaran S. Formulation and evaluation of transdermal files
`of terbutaline sulphate. Ind. J. Pharm.Sci. 1995: 57(5), 207.
`
`
`
`
`SCIENTIFIC PRESENTATIONS (POSTERS/PODIUM)
`
`CRS Annual Meeting 2015 (Submitted)
`162. Mechanism of drug penetration during short duration exposure to skin
`161. Transdermal iontophoretic delivery of propofol: Salt versus Captisol complex
`160. Transdermal Iron Replenishment Therapy
`159. Microreservoir design to minimize dose dumping from transdermal patches
`
`First European Conference Pharmaceutics, Reims, France
`158. Captisol enabled transdermal delivery of drugs by iontophoresis
`
`American Association of Pharmaceutical Scientsts Conference, 2014, San Diego, CA
`157. Transdermal permeation of diclofenac salts from sodium hyaluronate gels.
`156. Transdermal delivery of diclofenac salts using constant voltage iontophoresis and
` chemical permeation enhancers
`155. Caffeine anhydrous taste masking by Hot melt extrusion
`154. Hydrogel containing cyclodextrin complex of testosterone passive permeation and
` iontophoretic transport across the skin
`153. Plasma and brain pharmacokinetics of propofol
`152. Transdermal permeation of vit B12
`151. Intranasal delivery of flurocytosine
`150. A topical controlled release formulation for the treatment of postherpatic neuralgia
`149. Utilization of hot melt extrusion technique for developing controlled-release
` hyaluronic acid
`148. Controlled release injection for intrarticular treatment of osteoarthritis.
`147. Hot melt extrusion technique as a novel continuous process for manufacturing
` semi solid cream formulations.
`146. Alternate modes of delivery of ziconotide
`145. Intranasal controlled release gel using a biodegradable multiblock copolymer
`144.Does iontophoresis deliver drugs via non-follicular pathways?
`143. Paramagnetic medium to enhance the magnetophoretic transdermal delivery of
` drugs.
`142. Unveiling the mechanism of drug penetration into stratum corneum during the
` short duration exposure of topical formulation
`141. Transdermal delivery of folic acid (Vit B9) by iontophoresis.
`
`
`
`MYLAN - Ex. 1006, p. 10
`
`

`

`
`Neuroscience Conference-UMMC-Jackson –Jan 2014
`140. Nose to brain delivery of antimicrobial agents to treat opportunistic infections
`139. Chronic pain management by nose to CSF delivery of ziconotide
`138. Noninvasive induction of sedation and anesthesia
`
`Natural Products Research Center-Research Presentations Dec-2013
`137. Chronic pain management by intranasal administration of a conotoxin.
`136. Pain free injection technology to treat iron deficiency in pregnant women and
` children.
`135. Micro-reservoir patch: a simple solution to overcome dose dumping in defective
`
` transdermal patches
`134. Biophysical measures of human skin and correlations to barrier functions and drug
`
` transport properties
`133. Constant current dc iontophoresis for transdermal drug delivery: effects on skin
`
` biophysical properties
`132. Effect of pre-treatment with enhancers on the transdermal permeation of
` diclofenac sodium.
`131. Dermatokinetics of vitamin C, a well-known anti-ageing agent
`130. Solid dispersion of zaleplon cyclodextrin complexes and their efficiency evaluation
`129. Are cyclodextrins a viable tool for zotepine solubilization?
`128. In situ intranasal gels of ziconotide for enhanced CNS bioavailability.
`
`AAPS Annual Convention and Meeting 2014, San Antonio, TX
`127. Solid dispersion of zaleplon cyclodextrin complexes and their efficiency evaluation
`126. Are cyclodextrins a viable tool for zotepine solubilization?
`125. Nose to cerebrospinal fluid delivery of ziconotide
`124. In situ intranasal gels of ziconotide for enhanced CNS bioavailability.
`123. Formulation and evaluation of in situ intranasal gels for CNS delivery of
` cefotaxime
`122. A novel multiblock copolymer in situ gels for CNS delivery of cefotaxime
`121. Preparation and characterization of zotepine solid dispersions by cyclodextrin
`
`complexation.
`120. Zaleplon (BCS class II model drug) solubility enhancement by native and modified
`
`betacyclodextrins.
`119. Celecoxib (BCS class II model drug) solubility enhancement by cyclodextrin
`
`complexation
`118. Soluble iron microneedles: fabrication and in vitro evaluation
`117. Dermatokinetics of iron following application of soluble microneedles
`116. Transdermal delivery of iron dextran using soluble microneedles
`115. Percutaneous iron replishment therapy (PIRT): is passive transdermal delivery of iron
` possible?
`114. Potential risk of penetration of iron into skin from cosmetics
`113. Micro-reservoir patch: a simple solution to overcome dose dumping in defective
`
`MYLAN - Ex. 1006, p. 11
`
`

`

`transdermal patches
`
`112. Nifedipine pressure sensitive adhesive patches for treating diabetic wounds
`111. Polyols as plasticizers for efficient hot melt extrusion processaibility of
` maltodextrins
`110. Griseofulvin taste masked by hot melt extrusion for pediatric and geriatric
`
` reconstitutable suspension
`109. Effect of iontophoresis on the barrier properties of the stratum corneum in scar
` skin and normal skin in humans
`108. Combined use of microneedles and iontophoresis for transcutaneous sampling of
` drugs and biomarkers.
`107. Do regional differences in sub-epidermal water content determine the trans-
` epidermal water loss (TEWL)?
`106. Bioadhesive film forming formulation for topical delivery of drugs
`105. Continuous versus discontinuous application modes of iontophoresis on the trans-
`
`ungual delivery of itraconazole.
`104. Conductive topical nail lacquer for trans-ungual iontophoresis
`103. Losartan loaded hydrogel microparticles for delivery of drugs to treat chronic
` wounds
`102. Reverse iontophoresis for trans-ungual drug delivery.
`101. Effect of pre-treatment with alum on iontophoretic transdermal delivery of drugs
`100. Dermatokinetics of vitamin C, a well-known anti-ageing agent
`99. Convective transport of drugs into the skin from topical formulations
`98. Effect of pre-treatment with enhancers on dermatokinetics of diclofenac sodium
`97. Effect of mild hyperthermia (fever) on the iontophoretic transdermal delivery of
` drugs.
`96. Formulation and evaluation of drug-in-adhesive dermal patch of diclofenac sodium.
`
`AAPS Annual Convention and Meeting 2012, Chicago, IL
`95. Are cyclodextrins a viable tool for zotepine solubilization?
`94. Effect of molecular association on the transdermal permeation of propranolol
`hydrochloride
`93. Effect of molecular association on the transdermal permeation of promethazine
`hydrochloride
`92. Iontophoretic drug delivery for the treatment of scars
`91. Electroporation of skin using anionic cyclodextrins
`90. IVIVC of an immediate release formulations of a water insoluble drug, zotepine,
`
`produced by hot melt extrusion
`89. Iontophoretic delivery of liquid lipophilic drug
`88. Effect of pre-treatment with chemical permeation enhancers on iontophoretic
`delivery of drugs
`87. Delivery of propofol from SBE-β-CD complex
`86. Microdomain transdermal drug delivery
`85. Transdermal iontophoretic delivery of propofol – a central anesthetic
`84. Effect of pre-treatment with enhancers on the skin permeation of diclofenac
`
`MYLAN - Ex. 1006, p. 12
`
`

`

`83. Controlled release intralesional injection for the treatment of onychomycosis
`82. Trans-ungual iontophoretic delivery of itraconazole
`81. Topical treatment of hypertrophic scars
`
`AAPS Annual Convention and Meeting 2011, Washington, DC
`80. Formulation and evaluation of carnosic acid nanoparticulate system for
`
`upregulation of neurotropins in the brain upon intranasal administration.
`79. Effect of nail microporation and electropulse treatment on the trans-ungual
`
`permeation of terbinafine hydrochloride.
`78. Sublingual immunotherapy using allergens from house dust mites
`77. Nose to brain delivery of cefotaxime to treat meningitis
`76. Minimally invasive method for delivery of iron-dextran via transdermal route
`
`
`AAPS Annual Convention and Meeting 2010, New Orleans, LA
`75.Transdermal drug delivery by magnetophoresis in combination with chemical
` Permeation enhancers.
`74. Microdomain Transdermal Drug delivery systems (MTD).
`73. Enhancement of brain uptake of intranasally administered brain derived
` neurotrophic factor using chitosan as barrier modulating agent.
`72. Intranasal formulation of carnosic acid for upregulation of neurotrophins in the
` brain.
`71. Transdermal diffusion of drugs from powder form.
`70. Iontophoretic delivery across the proximal nail fold to target drugs to the nail
` matrix.
`
`PharmForum-SRDG Annual Meeting 2010, Oxford, MS
`69. Magnetophoresis for enhancing transdermal drug delivery: mechanistic studies
` and patch design. (Best podium presentation award)
`68. Intranasal formulation of carnosic acid for upregulation of neurotrophins in the
` brain. (Best poster award)
`
`AAPS Annual Convention and Meeting 2009, Los Angeles, CA
`67. Effect of Transcutol P on the in vitro trans-ungual permeation of terbinafine by
` iontophoresis.
`66. Development of an ex vivo toe model to study trans-ungual iontophoretic delivery
` of terbinafine.
`65. Effect of polyethylene glycols on the iontophoretic trans-ungual delivery of
` terbinafine.
`64. Iontophoretic delivery of gallium into human skin in vitro.
`63. Skin permeability and dermatokinetic studies of nanoparticles.
`62. Development of iontophoretic transdermal drug delivery system of alfuzosin
` hydrochloride.
`61. Albumin microspheres for oral iron delivery.
`60. Bilayered nail lacquer of terbinafine hydrochloride for treatme